Skip to main content
Premium Trial:

Request an Annual Quote

Premaitha Inks Russian Distribution Deal for Iona Prenatal Screening Test

NEW YORK (GenomeWeb) – Premaitha Health announced today that it has signed a deal making GeNext the exclusive distributor of its Iona non-invasive prenatal screening test in Russia.

The Iona test estimates the risk of a fetus being affected by Down syndrome and other serious genetic conditions by analyzing cell-free fetal DNA from a maternal blood sample. It received CE marking about a year ago.

Under the terms of the deal, GeNext will establish a central laboratory to act as a regional hub to process test samples. In the meantime, GeNext will send samples to Premaitha’s UK laboratory for processing.

Russia "is a new territory for Premaitha and it enables us to establish a local laboratory offering routine non-invasive prenatal screening," Premaitha CEO Stephen Little said in a statement. "The Russian market has significant potential for the Iona test, and through GeNext we are extremely well placed to accelerate market penetration across the country as awareness of the benefits of the test continues to grow."

This arrangement represents the sixth Premaitha has signed with regional partners in recent months. In February, the company signed on Visional Medical to distribute Iona in India. And in January, Premaitha announced that it had signed Iona service contracts with customers in Armenia and the Republic of Moldova. 

In 2015, Adgenix became the exclusive distributor of the Iona test in France, while Antisel and Servicios Geneticos OriGen began distributing the test in Greece and Chili, respectively.



The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.